How much do you know about the incidence of extramedullary disease in patients with multiple myeloma? Take our latest quiz to test your knowledge.
A meta-analysis on existing data on the use of autologous stem cell transplant in older patients with newly diagnosed multiple myeloma confirmed the need for randomized controlled trials.
Baseline left ventricular diastolic dysfunction may help predict the incidence of severe carfilzomib-induced cardiovascular adverse events in patients with multiple myeloma.
A randomized phase II trial investigated whether adding CX-01, a low anticoagulant heparin derivative, to standard care improves outcomes in older patients with acute myeloid leukemia.
Researchers evaluated survival and infusion time with combination isatuximab, pomalidomide, and low-dose dexamethasone vs pomalidomide plus low-dose dexamethasone alone in relapsed or refractory multiple myeloma.
Results from a second clinical trial examined the use of lenalidomide treatment in patients with high-risk smoldering multiple myeloma, where the standard of care has been observation.
A phase III study tested the combination conditioning regimen of busulfan plus melphalan vs standard melphalan alone for patients with newly diagnosed multiple myeloma undergoing transplantation.
Researchers looked at survival disparities between African American and Caucasian patients with multiple myeloma.
In this article, we present a case of a patient with relapsed Hodgkin lymphoma who responded to salvage chemotherapy incorporating brentuximab vedotin, a novel agent.
Patients with follicular lymphoma or diffuse large B-cell lymphoma with a low peripheral blood natural killer cell count at baseline had shorter time to progression.